












































The	discovery	of	novel	urease	 inhibitors	has	 attracted	 the	
attention	 of	 many	 research	 groups	 [1‐5]	 due	 to	 their	 wide	
applications	 against	 urea	 amidohydrolase,	 which	 is	 a	 nickel	
dependent	enzyme	that	 is	 responsible	 for	 the	bacteria	growth	
both	in	the	soil	and	in	the	human	body.	Urease	inhibition	is	not	
only	 responsible	 for	 maintaining	 human	 and	 animals	 good	
health	 but	 also	 has	 wide	 applications	 in	 agriculture	 [6].	




a	 reaction,	 which	 provides	 nitrogen	 for	 growth	 [13],	 and	 the	
enzyme	 also	 plays	 an	 important	 role	 in	 plant	 nitrogen	
metabolism	 during	 the	 germination	 process	 [14,15].	 The	
presence	 of	 urease	 activity	 in	 soil	 is	 exploited	 in	 the	
widespread	 agricultural	 practice	 of	 urea‐based	 fertilizer	
application	for	enhancing	crop	yields.	Unfortunately,	excessive	
levels	of	soil	urease	can	degrade	fertilizer	urea	too	rapidly	and	
result	 in	 phytopathic	 effects	 and	 loss	 of	 volatilized	 ammonia	
[16].	 The	 urease	 is	 a	 virulence	 factor	 in	 certain	 human	 and	
animal	pathogens;	it	participates	in	the	development	of	kidney	
stones,	 pyelonephritis,	 peptic	 ulcers,	 and	 other	 disease	 states	
[17‐20].	 The	 obvious	 remedy	 for	 treating	 bacterial	 infection	
with	antimicrobials,	however,	has	often	proven	futile	[21],	and	
only	a	few	combination	regiments	has	reached	clinical	practice.	
Thus	 the	 need	 for	 alternative	 or	 novel	 treatment	 to	 inhibit	
urease	activity	 for	 the	possible	development	of	highly	needed	
therapy	for	urease	mediated	bacterial	infections	is	evident.	
Heterocycles	 especially	 1,3,4‐oxadiazole	 are	 some	 of	 the	
most	 important	 motifs	 in	 medicinally	 important	 compounds.	
The	 substituted	 oxadiazoles	 serve	 both	 as	 biomimetic	 and	
reactive	 pharmacophores.	 Such	 compounds	 offer	 a	 privileged	
motif	 in	 medicinal	 chemistry;	 such	 as	 antidiabetic	 [22],	
anticancer	 [23],	 antialzimer	 activity,	 inhibitors	 of	 glycogen	
synthase	 kinase‐3β	 [24],	 insecticidal	 [25],	 bactericidal	 [26],	
hypoglycemic	 [27],	 analgesic,	 anticonvulsive,	 antiemetic,	
diuretic	 [28],	 muscle	 relaxant	 [29,30],	 herbicidal	 [31,32]	 and	
fungicidal	activity	[33,34].		
Since	 the	 discovery	 of	 potent	 urease	 inhibitors	 is	 an	
important	 area	 of	 pharmaceutical	 research,	 therefore	 several	
classes	 of	 compounds	 have	 been	 tested	 and	 found	 to	 exhibit	
significant	 inhibitory	activities	against	urease	enzyme	[35‐38].	
Similarly,	 5‐membered	 heterocycles	 such	 as	 1,3,4‐oxadiazoles	
and	 1,2,4‐triazoles	 are	 also	 known	 to	 inhibit	 the	 bacterial	
ureases	 [39‐41].	 Previously	 we	 have	 tested	 urease	 inhibitors	
activities	 of	 some	 of	 1,3,4‐oxadiazoles	 [41],	 encouraged	 by	








Melting	 points	 were	 determined	 on	 a	 Büchi	 434	 melting	
point	apparatus	and	are	uncorrected.	NMR	was	performed	on	
Bruker	 AM	 300,	 400	 and	 500	 MHz.	 CHN	 analysis	 was	
performed	 on	 a	 Carlo	 Erba	 Strumentazion‐Mod‐1106	 Italy.	
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Infrared	 Spectra	 (IR)	 was	 recorded	 on	 JASCO	 IR‐A‐302	
spectrometer.	 Electron	 Impact	 Mass	 Spectra	 (EI‐MS)	 were	
recorded	 on	 a	 Finnigan	 MAT‐31A	 Germany.	 Thin	 Layer	
chromatography	(TLC)	was	performed	on	pre‐coated	silica	gel	






of	 enzyme	 (Jack	 bean	 Urease)	 solution	 and	 55	 µL	 of	 buffers	
containing	 100	 mM	 urea	 were	 incubated	 with	 5	 µL	 of	 test	
compounds	(1.0	mM	concentration)	at	30	oC	for	15	min	in	96‐
well	 plates.	 Urease	 activity	 was	 determined	 by	 measuring	
ammonia	 production	 using	 the	 indophenol	 method	 as	
described	by	Weatherburn	 [42].	 Briefly,	 45	µL	 each	 of	 phenol	
reagent	 (1%	 (w/v)	 phenol	 and	 0.005%	 (w/v)	 sodium	
nitroprusside)	 and	70	µL	of	 alkali	 reagent	 (0.5%	 (w/v)	NaOH	
and	0.1%	active	chlorine,	NaOCl)	were	added	to	each	well.	The	
increasing	absorbance	at	630	nm	was	measured	after	50	min,	
using	 a	 microplate	 reader	 (Molecular	 Device,	 USA).	 All	
reactions	were	performed	in	triplicate	in	a	final	volume	of	200	
µL.	 The	 results	 (change	 in	 absorbance	 per	 min.)	 were	
processed	 by	 using	 SoftMax	 Pro	 software	 (Molecular	 Device,	
USA).	 All	 the	 assays	 were	 performed	 at	 pH	 =	 8.2	 (0.01	 M	
K2HPO4.3H2O,	 1.0	 mM	 EDTA	 and	 0.01	 M	 LiCl2).	 Percentage	
inhibitions	 were	 calculated	 from	 the	 formula	 100‐









which	 was	 placed	 in	 a	 screw‐capped	 thick‐walled	 Teflon®	
vessel.	Microwave‐irradiation	(MW	domestic	type	oven	900	W	
with	a	 frequency	2450	MHz,	Dawlance,	Pakistan)	was	applied	
for	 3‐7	 min.	 After	 the	 completion	 of	 reaction	 (TLC	 analysis),	
ethanol	was	 added	 into	 reaction	mixture	 and	 filtered.	 Filtrate	
was	 evaporated;	 distilled	 water	 was	 added	 to	 semi‐solid	
material	 and	 acidified	 with	 hydrochloric	 acid	 to	 pH	 =	 4.	
Precipitates	 so	 obtained	were	 filtered	 and	 dried	 to	 afford	 off	
white	 solid	 compound	 2a‐r	 and	 then	 recrystallized	 from	
ethanol:water	(50:50)	mixture	(Table	1).	
5(2′‐Hydroxyphenyl‐1,3,4‐oxadiazole‐2(3H)‐thione	 (2a):	




Acetone‐d6,	 δ,	 ppm):	 14.33	 (bs,	 1H,	 NH),	 8.84	 (br	 s,	 1H,	 OH),	
7.61	(m,	1H,	H‐4´),	7.08	(d,	1H,	H‐3´),	7.07	(dd,	1H,	J	=	8.1	Hz,	J	=	
6.4	Hz,	H‐5´),	7.01	(1H,	J	=	7.7	Hz,	J	=	5.0,	J	=	1.5	Hz,	H‐6´).	Anal.	
calcd.	 for	 C8H6N2O2S:	 C,	 49.47;	 H,	 3.11;	 N,	 14.42.	 Found:	 C,	
49.49;	H,	3.15;	N,	14.46%.	
5(4′‐Methoxyphenyl)‐1,3,4‐oxadiazole‐2(3H)‐thione	 (2b):	
Yield:	 1.41	 g	 (94%).	 M.p.:	 190‐191	 oC.	 Rf	 =	 0.65	 (Ethyl	
acetate:hexane	=	1:1).	FT‐IR	(KBr,	νmax,	cm‐1):	3399	(NH),	1659	
(C=N),	 1333	 (C=S),	 1019	 (C‐O).	 MS	 (m/z,	 %):	 208	 (M+,	 100),	
148	 (54),	 135	 (12),	 133	 (88),	 107	 (3),	 105	 (20),	 92	 (10),	 77	
(13),	64	(14),	51	(18).	1H	NMR	(500	MHz,	CD3OD,	δ,	ppm):14.23	
(br	s,	1H,	NH),	7.84(d,	2H,	J	=	8.8	Hz,	H‐2´/6´),	7.05	(d,	2H,	J	=8.8	












1.39	 g	 (93%).	 M.p.:	 >250	 oC	 (Decompose).	 Rf	 =	 0.64	 (Ethyl	
acetate:hexane	=	1:1).	FT‐IR	(KBr,	νmax,	cm‐1):	3366	(NH),	1632	




2′,6′).	 Anal.	 calcd.	 for	 C8H5N3O3S:	 C,	 43.05;	 H,	 2.26;	 N,	 18.83.	
Found:	C,	43.01;	H,	2.22;	N,	18.86%.	
5(3′,4′,5′‐Trimethoxyphenyl)‐1,3,4‐oxadiazole‐2(3H)‐thione	
(2e):	 Yield:	 1.36	 g	 (91%).	 M.p.:	 175‐176	 oC.	 Rf	 =	 0.59	 (Ethyl	
acetate:hexane	=	1:1).	FT‐IR	(KBr,	νmax,	cm‐1):	3171	(NH),	1579	
(C=N),	1331	(C=S),	1041	(C‐O‐C).	MS	(m/z,	%):	268	(100),	208	
(32),	 193	 (70),	 178	 (12),	 167	 (6),	 152	 (7),	 135	 (13).	 1H	NMR	
(300	MHz,	DMSO‐d6,	δ,	ppm):	14.81	(br	s,	1H,	NH),	7.09	(s,	2H,	
H‐2´,6´),	 3.84	 (s,	 6H,	 OCH3‐3´/5´),	 3.72	 (s,	 3H,	 OCH3‐4´).	 Anal.	

































=	 1:1).	 FT‐IR	 (KBr,	 νmax,	 cm‐1):	 3431	 (NH),	 1641	 (C=N),	 1328	























Entry	 Compound	 R	 Time	[min] Yield	[%] IC50	±	S.E.M	(μM)
1	 2a	 o‐OHC6H4	 5 89 N.	A.	
2	 2b	 p‐CH3OC6H4	 5 94 N.	A.	
3	 2c	 m‐NO2C6H4	 3 92 15.55	±	2.37	
4	 2d	 p‐NO2C6H4	 3	 93	 166.35	±	1.13	
5	 2e	 3,4,5‐(CH3O)3C6H2	 5	 91	 59.49	±	0.22	
6	 2f	 o‐ClC6H4	 6 98 19.27	±	1.94	
7	 2g	 m‐ClC6H4	 5	 95	 63.50	±	1.33	
8	 2h	 p‐ClC6H4	 5 92 N.	A.	
9	 2i	 p‐FC6H4	 3 96 71.67	±	0.90	
10	 2j	 o‐BrC6H4	 7 79 12.60	±	0.92	
11	 2k	 m‐BrC6H4	 5 88 N.	A.	
12	 2l	 p‐BrC6H4	 4 93 13.03	±	1.80	
13	 2m	 m‐CH3C6H4	 5 96 N.	A.	
14	 2n	 p‐CH3C6H4	 4	 98	 N.	A.	
15	 2o	 C5H4N	 4 94 N.	A.	
16	 2p	 o‐NH2C6H4	 6	 86	 19.03	±	0.72	
17	 2q	 3‐CH3‐4‐NO2C6H3	 5	 89	 13.62	±	1.49	
18	 2r	 C8H17	 6	 73	 21.33	±	1.21	





FT‐IR	 (KBr,	 νmax,	 cm‐1):	 1069	 (C‐O‐C),	 1631	 (C=N),	 3181	
(NH).	 EI‐MS	 (m/z,	%):	 258	 (M+,	 94),	 256	 (M+,	 100),	 198	 (86),	
197	(9),	196	(96),	185	(12),	183	(17),	157	(16),	155	(14),	117	
(24),	 102	 (14),	 76	 (15).	 1H	 NMR	 (500	MHz,	 CD3OD,	 δ,	 ppm):	
14.64	(bs,	1H,	NH),	8.03	(d,	1H,	J	=	1.5	Hz,	H‐2´),	7.87	(d,	1H,	J	=	
8.0	Hz,	H‐6´),	7.74	(dd,	1H,	J	=	8.0	Hz,	J	=	1.5	Hz,	H‐4´),	7.46	(t,	





(NH).	MS	 (m/z,	%):	258	 (M+,	60),	 256	 (M+,	59),	198	 (47),	196	
(46),	185	(9),	184	(69),	183	(15),	181	(6),	157	(7),	155	(8),	117	
(6),	 76	 (7),	 50	 (8).	 1H	NMR	 (500	MHz,	CD3OD,	δ,	 ppm):	14.59	
(bs,	1H,	NH),	7.8	(d,	2H,	J	=	8.4	Hz,	H‐2′/6′),	7.7	(d,	2H,	 J	=	8.4	
Hz,	H‐3′/5′).	Anal.	 calcd.	 for	C8H5BrN2OS:	 C,	 34.37;	H,	 1.96;	N,	
10.90.	Found:	C,	34.32;	H,	1.98;	N,	10.96%.	
5(3′‐Methylphenyl‐1,3,4‐oxadiazole‐2(3H)‐thione	 (2m):	



























Yield:	 1.31	 g	 (86	 %).	 M.p.:	 156‐157	 oC.	 Rf	 =	 0.68	 (Ethyl	
acetate:hexane	 =	 1:1).	 FT‐IR	 (KBr,	 νmax,	 cm‐1):	 1054	 (C‐O‐C),	
1616	(C=N),	3585	(NH).	MS	(m/z,	%):	193	(M+,	17),	177	(100),	




7.0	 Hz,	 H‐5´).	 Anal.	 calcd.	 for	 C8H7N3OS:	 C,	 49.73;	 H,	 3.65;	 N,	
21.75.	Found:	C,	49.71;	H,	3.63;	N,	21.74%.	
5‐(3′‐Methyl,4′‐nitro	 phenyl)‐1,3,4‐oxadiazole‐2(3H)‐thione	
(2q):	 Yield:	 1.33	 g	 (89%).	 M.p.:	 240‐241	 oC.	 Rf	 =	 0.58	 (Ethyl	
acetate:hexane	 =	 1:1).	 FT‐IR	 (KBr,	 νmax,	 cm‐1):	 1100	 (C‐O‐C),	
1627	(C=N),	3395	(NH).	EI‐MS	(m/z,	%):	237	(M+,	100),	(207),	






5‐n‐Octyl‐1,3,4‐oxadiazole‐2(3H)‐thione	 (2r):	 Yield:	 1.09	 g	
(73%).	M.p.:	 55‐56	 oC.	 Rf	 =	 0.59	 (Ethyl	 acetate:hexane	 =	 1:1).	
FT‐IR	 (KBr,	νmax,	 cm‐1):	 3384	 (NH),	 2955	 (CH2‐aliphatic)	 1666	
(C=N),	1315	(C=S),	1089	(C‐O).	MS	(m/z,	%):	214	(M+,	8),	181	
(10),	 158	 (3),	 143	 (4).	 1H	NMR	 (500	MHz,	DMSO‐d6,	 δ,	 ppm):	
14.26	(bs,	1H,	NH),	2.70	(t,	2H,	J	=	7.3	Hz,	CH2‐1´),	1.62	(q,	2H,	,	J	
=	7.3	Hz,	CH2‐2´),	1.26	(m,	10H,	(CH2)5),	0.84	(t,	3H,	J	=	6.5	Hz,	





The	 reaction	 of	 hydrazides	 with	 carbon	 disulfide,	 in	 the	
presence	 of	 potassium	 hydroxide,	 and	 loaded	 over	 alumina	
under	 microwave	 irradiation	 afforded	 5‐substituted‐1,3,4‐
oxadiazole‐2(3H)‐thiones	in	good	to	excellent	yields	(Table	1).	
Presence	 of	 electron	 withdrawing	 substituents	 enhances	 the	
conversion	 rate	 and	 reaction	 completed	 in	 short	 time.	









The	 bioactivity	 was	 assessed	 according	 to	 literature	
protocol	and	thiourea	was	used	as	a	standard	inhibitor	having	
IC50	 value	 21	 μM	 (Table	 1).	 All	 the	 synthesized	 compounds	
were	 tested	 against	 urease	 inhibitory	 effects,	 and	 activity	
ranges	 from	 12.60	 ±	 0.92	 μM	 to	 166.35	 ±	 1.13	 μM.	 Seven	
compounds	2c,	2f,	2j,	2l,	2p,	2q	and	2r	demonstrated	excellent	
inhibitory	 activity	 in	 the	 range	 12.60	 μM‐21.33	 μM,	 whereas	





group	 with	 meta‐methyl	 group	 2q	 displayed	 a	 remarkable	
progress	 in	 the	 urease	 inhibition	 (13.62	 ±	 1.49	 μM).	 The	
presence	of	nitro	group	on	para‐position	2d	also	presented	an	
excellent	inhibitory	activity	(15.55	±	2.37	μM)	while	para‐nitro	
group	 containing	 compound	 2c	 displayed	 poor	 inhibitory	
activity	(166.35	±	1.13	μM).	It	was	observed	that	compound	2f	
containing	 ortho‐chloro‐	 substituted	 phenyl	 motif	 showed	
excellent	inhibition	(19.27	±	1.94	μM),	meta‐chloro	substituted	
compound	 2g	 presented	 significant	 inhibition	 (63.50	 ±	 1.33	
μM)	 and	whereas	para‐chloro‐	 substituted	 compound	2h	was	
found	 to	 be	 inactive.	 Generally,	 it	 was	 observed	 that	
compounds	 having	 para	 substituted	 phenyl	 motifs	 showed	
poor	 inhibition.	 Among	 bromo	 group	 substituted	 derivatives	
2j‐l,	 ortho‐bromo	 substituted	 phenyl	 group	 in	 compound	 2j	
displayed	tremendous	inhibition	(12.60	±	0.92	μM)	while	meta	
substituted	 bromo	 compound	2k	 is	 inactive.	 The	 presence	 of	
bromo	 group	 on	 para‐position	 of	 phenyl	 motif	 2l	 caused	 an	
outstanding	urease	inhibition	(13.03	±	1.80	μM).	
From	 the	 structure	 activity	 relationship	 we	 found	 that	
declines	 in	 activity	 are	 rationalized	 that	 as	 the	 steric	






In	 summary,	we	 have	 efficiently	 extended	 our	microwave	
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